ABSTRACT Twenty seven aspirin sensitive asthmatic patients were studied to determine the relationship between non-specific bronchial responsiveness to inhaled histamine and the degree of sensitivity to aspirin (aspirin threshold dose). No correlation was found between provocative concentration of histamine (PC20H) and aspirin threshold dose. In 11 patients the influence of aspirin desensitisation on bronchial reactivity to inhaled histamine was examined. Mean PC20H measured the day after the patients were desensitised to 600 mg of aspirin did not change significantly from the values before desensitisation. These observations suggest that sensitivity to aspirin and non-specific bronchial hyperreactivity in asthmatic patients are independent phenomena.
Aspirin sensitivity occurs in 4-10% of asthmatic patients and usually coincides with sensitivity to other non-steroidal anti-inflammatory drugs.' 2 Aspirin induced bronchospasm is not due to allergy but is thought to result from the interference of the drug with arachidonic acid metabolism in the lungs.34 Inhibition of cyclo-oxygenase by aspirin or other non-steroidal anti-inflammatory drugs may induce a decrease in synthesis of bronchodilating prostaglandins, leading to bronchoconstriction in sensitive asthmatics. Alternatively aspirin may activate the second pathway of arachidonic acid metabolism, resulting in overproduction of leukotrienes with strong bronchoconstrictor activity. 5 The presence of bronchial hyperreactivity has been suggested as an essential factor for the development of bronchoconstriction after aspirin.2 Furthermore, bronchial responsiveness to several non-specific stimuli in aspirin sensitive asthmatic patients differs from that observed in patients not sensitive to aspirin.68 We were interested in study-aspirin in aspirin sensitive asthmatic subjects. Since safe methods of desensitisation to aspirin have recently been developed9-" we were able to investigate the influence of that procedure on bronchial responsiveness to histamine.
Methods

PATIENTS
The study included 27 patients with asthma and sensitivity to aspirin, 15 male and 12 female, ranging in age from 22 to 60 years (mean 37.4). All Bronchial hyperreactivity to histamine in aspirin sensitive asthmatics aspirin threshold dose, seems to reflect the severity of the underlying disease process at a given moment.220 We might expect, then, that the level of bronchial hyperreactivity measured by inhaled histamine (PC20H) should predict the dose of aspirin that will trigger bronchoconstriction in aspirin challenge. In the present study, however, we could not find any correlation between the degree of sensitivity to aspirin, as reflected by aspirin threshold dose, and bronchial responsiveness to histamine. Our results suggest that the degree of non-specific responsiveness is not an essential determinant of the bronchoconstrictor response to aspirin in aspirin sensitive asthmatics. Consistent with this idea is the observation that the individual variability in susceptibility to aspirin (that is, change in aspirin threshold doses or even loss of sensitivity) concerns not only bronchoconstrictive responses but also the extrabronchial symptoms of adverse reactions to aspirin in asthmatic patients.29 These changes in the extrabronchial manifestations of aspirin sensitivity are apparently not related to the level of non-specific bronchial hyperreactivity. This finding points to the conclusion that individual sensitivity to aspirin is determined by factors other than bronchial hyperreactivity but common to bronchial and extrabronchial manifestations of aspirin induced adverse reactions. According to Szczeklik et al,34 the level of susceptibility of tissue cyclo-oxygenase to the inhibitory action of non-steroidal anti-inflammatory drugs may be the factor determining sensitivity to aspirin. Our results cannot, however, be interpreted unequivocally in terms of mechanisms of bronchial hyperreactivity since aspirin was given orally and individual variation in absorbtion and metabolism of the drug was not taken into account. On the other hand, an individual aspirin threshold dose should be considered to depend on several factors, such as aspirin absorption and metabolism and even target molecule (cyclo-oxygenase?) susceptibility. Aspirin threshold dose seems therefore to be a good clinical measure of aspirin sensitivity in a given patient.
It has been suggested that the bronchi of aspirin sensitive patients are dependent more on the bronchodilating activity of prostaglandin E2 (PGE2) than the bronchi of non-sensitive asthmatics.3 The presumption has further been supported by observations of different patterns of bronchial responsiveness to prostaglandins, histamine, and exercise in that group of patients.68 If the mechanism of bronchial hyperreactivity in aspirin sensitive asthmatic patients depended mainly on prostaglandins one would expect that profound disturbances of prostaglandin metabolism evoked by aspirin desensitisation2' would significantly influence non-specific responsiveness of the bronchi. This apparently did not occur in our patients: neither the mean basal bronchial muscle tone, reflected in the FEV,, nor the mean PC20 histamine changed significantly after aspirin desensitisation. Similarly, aspirin desensitisation does not influence skin reactivity to intradermally injected histamine and codeine phosphate, although it may change skin responses to compound 48/80, a mast cell degranulator.2 ' 22 Recently we have noted that 600 mg of aspirin administered daily for four weeks after desensitisation significantly increased histamine thresholds in most of 13 aspirin sensitive asthmatic patients and the changes in bronchial responsiveness paralleled the clinical improvement during aspirin treatment (unpublished observations). Taken together, these observations suggest that aspirin desensitisation itself does not affect bronchial hyperreactivity but prolonged aspirin treatment may influence the nonspecific responsiveness of the bronchial tree. Walters23 showed that high single doses of non-steroidal anti-inflammatory drugs may modify bronchial responsiveness to histamine in asthmatic subjects sensitive to aspirin. In our study the cumulative doses of aspirin were administered during several days and perhaps it would be more relevant to test the influence of high single doses of aspirin or indomethacin on bronchial responsiveness to histamine in aspirin sensitive patients in the aspirin refractory state.
The mechanism of aspirin desensitisation remains obscure. As we have suggested previously, the aspirin induced refractory state in the bronchi might be related to persistent cyclo-oxygenase inhibition by aspirin during desensitisation and during that time the functional balance in the bronchi might be based on prostaglandin independent regulatory mechanisms that are not susceptible to the intervention of non-steroidal anti-inflammatory drugs." Present data seem to support this suggestion. From this study we may conclude also that the preservation of the airway responsiveness to histamine after desensitisation indicates that the tolerance to aspirin is neither the result of non-specific depression of bronchial smooth muscle nor the effect of local tachyphylaxis to endogenous histamine.
